7-days of FREE Audio papers, translation & more with Prime
7-days of FREE Prime access
7-days of FREE Audio papers, translation & more with Prime
7-days of FREE Prime access
https://doi.org/10.1200/jco.2004.22.14_suppl.3016
Copy DOIJournal: Journal of Clinical Oncology | Publication Date: Jul 15, 2004 |
Citations: 5 |
3016 Background: Relapsed aggressive Non-Hodgkin's Lymphoma (NHL) has a poor prognosis; and new treatments are needed. Angiogenesis is increased in aggressive NHL, and may be a target in these diseases. Low dose chronic chemotherapy (metronomic chemotherapy, MC) inhibits angiogenesis in vitro. Since COX-2 may promote neoplasia and tumour angiogenesis, selective COX-2 inhibitors may have anti-tumour effects in NHL.We assessed response to MC and COX-2 inhibition and toxicity in patients (pts) with relapsed aggressive NHL following anthracycline based chemotherapy. Methods: Pts with measureable disease and normal renal function received cyclophosphamide 50 mg po qd + celecoxib 400 mg po bid. Pts were assessed clinically monthly x 6 then q 2 mos; CT scans q 3 mos, serial plasma VEGF and TSP-1 levels. Pharmacokinetics (PK)and serial LN biopsies for COX-2 IHC were performed in selected pts. Serial circulating endothelial cells (CEC) and their precursors (CEP) were measured by flow cytometry. Results: To date 21...
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.